UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole Blood
Background: Clinical features of severe coronavirus disease 2019 (COVID-19) predominantly include respiratory symptoms and exacerbated multi-organ complications, especially in patients with comorbidities. Cellular immunity, including lymphocytes, is a critical factor in combating SARS-CoV-2 infectio...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cell and BioPharmaceutical Institute
2025-03-01
|
| Series: | MCBS (Molecular and Cellular Biomedical Sciences) |
| Online Access: | https://cellbiopharm.com/ojs/index.php/MCBS/article/view/538 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850182014459707392 |
|---|---|
| author | Winna Soleha Heri Wibowo Murdani Abdullah Saraswati Pradipta Lucky Novita Syari Isabella Kurnia Liem Arleni Bustami Anna Rozaliyan |
| author_facet | Winna Soleha Heri Wibowo Murdani Abdullah Saraswati Pradipta Lucky Novita Syari Isabella Kurnia Liem Arleni Bustami Anna Rozaliyan |
| author_sort | Winna Soleha |
| collection | DOAJ |
| description | Background: Clinical features of severe coronavirus disease 2019 (COVID-19) predominantly include respiratory symptoms and exacerbated multi-organ complications, especially in patients with comorbidities. Cellular immunity, including lymphocytes, is a critical factor in combating SARS-CoV-2 infection. However, immune dysregulation occurs in severe COVID-19 patients, characterized by cytokine storm and lymphopenia. The effectiveness of mesenchymal stem cell (MSC) therapies for COVID-19 is being assessed. The secretome released by MSC functions similarly to the cells themselves as an immunomodulator, offering potential advantages in terms of safety and cost-effectiveness. This study was conducted to assess the effect of umbilical cord MSC-derived (UC-MSC) secretome treatment on lymphocyte count and soluble programmed cell death-1 (sPD-1) levels in severe COVID-19 patient's whole blood.
Materials and methods: Twelve whole blood samples from healthy individuals and severe COVID-19 patients were analyzed for lymphocyte count and functional activation using flow cytometry, along with sPD-1 level measurement in pre-treatment and post-secretome conditions.
Results: The lymphocyte count in severe COVID-19 patients was significantly decreased, particularly for T cells and NK cells, indicating lymphopenia. Following secretome treatment, CD4+ T cell counts significantly increased compared to pre-treatment, although this change was not significant in the negative control group. Additionally, there was a minimal reduction in B cell count and an increase in sPD-1 levels. Elevated sPD-1 may alleviate T cell exhaustion by interfering with PD-1 binding to programmed death-ligand 1 (PD-L1).
Conclusion: Administration of UC-MSC secretome to the whole blood of severe COVID-19 patients suggested immune improvement, with significant increases in CD4+ T cell counts, enhanced B cell survival, and elevated sPD-1 levels.
Keywords: COVID-19, cellular immunity, lymphocytes, secretome, MSC |
| format | Article |
| id | doaj-art-ed60dac07a1844e793fc1094706de574 |
| institution | OA Journals |
| issn | 2527-4384 2527-3442 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Cell and BioPharmaceutical Institute |
| record_format | Article |
| series | MCBS (Molecular and Cellular Biomedical Sciences) |
| spelling | doaj-art-ed60dac07a1844e793fc1094706de5742025-08-20T02:17:46ZengCell and BioPharmaceutical InstituteMCBS (Molecular and Cellular Biomedical Sciences)2527-43842527-34422025-03-0191394710.21705/mcbs.v9i1.538151UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole BloodWinna Soleha0Heri Wibowo1Murdani Abdullah2Saraswati Pradipta3Lucky Novita Syari4Isabella Kurnia Liem5Arleni Bustami6Anna Rozaliyan7Master’s Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, JakartaDepartment of Parasitology, Faculty of Medicine, Universitas Indonesia, JakartaDepartment of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, JakartaIntegrated Laboratory of Medical Faculty, Universitas Indonesia, JakartaIntegrated Laboratory of Medical Faculty, Universitas Indonesia, JakartaDepartment of Anatomy, Faculty of Medicine, Universitas Indonesia, JakartaMaster’s Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, JakartaDepartment of Parasitology, Faculty of Medicine, Universitas Indonesia, JakartaBackground: Clinical features of severe coronavirus disease 2019 (COVID-19) predominantly include respiratory symptoms and exacerbated multi-organ complications, especially in patients with comorbidities. Cellular immunity, including lymphocytes, is a critical factor in combating SARS-CoV-2 infection. However, immune dysregulation occurs in severe COVID-19 patients, characterized by cytokine storm and lymphopenia. The effectiveness of mesenchymal stem cell (MSC) therapies for COVID-19 is being assessed. The secretome released by MSC functions similarly to the cells themselves as an immunomodulator, offering potential advantages in terms of safety and cost-effectiveness. This study was conducted to assess the effect of umbilical cord MSC-derived (UC-MSC) secretome treatment on lymphocyte count and soluble programmed cell death-1 (sPD-1) levels in severe COVID-19 patient's whole blood. Materials and methods: Twelve whole blood samples from healthy individuals and severe COVID-19 patients were analyzed for lymphocyte count and functional activation using flow cytometry, along with sPD-1 level measurement in pre-treatment and post-secretome conditions. Results: The lymphocyte count in severe COVID-19 patients was significantly decreased, particularly for T cells and NK cells, indicating lymphopenia. Following secretome treatment, CD4+ T cell counts significantly increased compared to pre-treatment, although this change was not significant in the negative control group. Additionally, there was a minimal reduction in B cell count and an increase in sPD-1 levels. Elevated sPD-1 may alleviate T cell exhaustion by interfering with PD-1 binding to programmed death-ligand 1 (PD-L1). Conclusion: Administration of UC-MSC secretome to the whole blood of severe COVID-19 patients suggested immune improvement, with significant increases in CD4+ T cell counts, enhanced B cell survival, and elevated sPD-1 levels. Keywords: COVID-19, cellular immunity, lymphocytes, secretome, MSChttps://cellbiopharm.com/ojs/index.php/MCBS/article/view/538 |
| spellingShingle | Winna Soleha Heri Wibowo Murdani Abdullah Saraswati Pradipta Lucky Novita Syari Isabella Kurnia Liem Arleni Bustami Anna Rozaliyan UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole Blood MCBS (Molecular and Cellular Biomedical Sciences) |
| title | UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole Blood |
| title_full | UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole Blood |
| title_fullStr | UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole Blood |
| title_full_unstemmed | UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole Blood |
| title_short | UC-MSCs Secretome Induces Proliferation of CD4+ T Cells, CD8+ T Cells, NK Cells, and Increases sPD-1 Levels in Severe COVID-19’s Whole Blood |
| title_sort | uc mscs secretome induces proliferation of cd4 t cells cd8 t cells nk cells and increases spd 1 levels in severe covid 19 s whole blood |
| url | https://cellbiopharm.com/ojs/index.php/MCBS/article/view/538 |
| work_keys_str_mv | AT winnasoleha ucmscssecretomeinducesproliferationofcd4tcellscd8tcellsnkcellsandincreasesspd1levelsinseverecovid19swholeblood AT heriwibowo ucmscssecretomeinducesproliferationofcd4tcellscd8tcellsnkcellsandincreasesspd1levelsinseverecovid19swholeblood AT murdaniabdullah ucmscssecretomeinducesproliferationofcd4tcellscd8tcellsnkcellsandincreasesspd1levelsinseverecovid19swholeblood AT saraswatipradipta ucmscssecretomeinducesproliferationofcd4tcellscd8tcellsnkcellsandincreasesspd1levelsinseverecovid19swholeblood AT luckynovitasyari ucmscssecretomeinducesproliferationofcd4tcellscd8tcellsnkcellsandincreasesspd1levelsinseverecovid19swholeblood AT isabellakurnialiem ucmscssecretomeinducesproliferationofcd4tcellscd8tcellsnkcellsandincreasesspd1levelsinseverecovid19swholeblood AT arlenibustami ucmscssecretomeinducesproliferationofcd4tcellscd8tcellsnkcellsandincreasesspd1levelsinseverecovid19swholeblood AT annarozaliyan ucmscssecretomeinducesproliferationofcd4tcellscd8tcellsnkcellsandincreasesspd1levelsinseverecovid19swholeblood |